Liposomes as nanomedical devices

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 975-999

  Bozzuto, Giuseppina ^a,b   Molinari, Agnese ^b  

^a CNR   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Drug delivery; Liposomes; Nanomedicine; Ultrastructure

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CISPLATIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; HEPATITIS A VACCINE; INFLUENZA VACCINE; LIPOSOME; PACLITAXEL; VINCRISTINE SULFATE; DRUG CARRIER;

CELL INTERACTION; CLINICAL EFFECTIVENESS; DRUG DELIVERY SYSTEM; ENCAPSULATION; GEL PERMEATION CHROMATOGRAPHY; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LIGHT SCATTERING; MICROFLUIDICS; PARTICLE SIZE; PHYSICAL CHEMISTRY; REVIEW; TRANSMISSION ELECTRON MICROSCOPY; HUMAN; NANOMEDICINE;

DRUG CARRIERS; HUMANS; LIPOSOMES; NANOMEDICINE;

EID: 84922187503     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S68861     Document Type: Review

References (315)

1. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 1964;8:660-668.
2. Bangham AD, Hill MW, Miller NG. Preparation and use of liposomes as models of biological membranes. In: Korn ED, editor. Methods in Membrane Biology. Vol 1. New York: Plenum; 1974:1-68.
3. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine. 2013;9:1-14.
4. Felice B, Prabhakaran MP, Rodríguez AP, Ramakrishna S. Drug delivery vehicles on a nano-engineering perspective. Mater Sci Eng C Mater Biol Appl. 2014;41:178-195.
5. Fanciullino R, Ciccolini J. Liposome-encapsulated anticancer drugs: still waiting for the magic bullet? Curr Med Chem. 2009;16:4361-4373.
6. Euliss LE, DuPont JA, Gratton S, DeSimone J. Imparting size, shape, and composition control of materials for nanomedicine. Chem Soc Rev. 2006;35:1095-1104.
7. Papahadjopoulos D, Kimelberg HK. Phospholipid vesicles (liposomes) as models for biological membranes: their properties and interactions with cholesterol and proteins. In: Progress in Surface Science. Vol. Oxford: Pergamon; 1973:141-149.
8. Frolov VA, Shnyrova AV, Zimmerberg J. Lipid polymorphisms and membrane shape. Cold Spring Harb Perspect Biol. 2011;3:a004747.
9. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1:297-315.
10. Betageri GV, Parsons DL. Drug encapsulation and release from multilamellar and unilamellar liposomes. Int J Pharm. 1992; 81:235-241.
11. Niven RW, Speer M, Schreier H. Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm Res. 1991; 8:217-221.
12. Schechter E. Aspects structuraux et fonctionnels. In: Schechter E, Rossignol B, editors. Biochimie et Biophysique des Membranes. Paris: Dunod; 2002.
13. Hosta-Rigau L, Zhang Y, Teo BM, Postma A, Städler B. Cholesterol-a biological compound as a building block in bionanotechnology. Nanoscale. 2013;5:89-109.
14. Bitounis D, Fanciullino R, Iliadis A, Ciccolini J. Optimizing druggability through liposomal formulations: new approaches to an old concept. ISRN Pharm. 2012;2012:738432.
15. Milla P, Dosio F, Cattel L. PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab. 2012;13:105-109.
16. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988;85:6949-6953.
17. Allen TM. Long-circulating (Stealth) liposomes: therapeutic applications. In: Puisieux F, Couvreur P, Delattre J, Devissaguet JP, editors. Liposomes: New Systems and New Trends in Their Applications. Paris: Editions de Santé; 1995:125-155.
18. Gómez-Hens A, Fernández-Romero JM. Analytical methods for the control of liposomal delivery systems. Trends Analyt Chem. 2006;25: 167-178.
19. Mozafari MR, Johnson C, Hatziantoniou S, Demetzos C. Nanoliposomes and their applications in food nanotechnology. J Liposome Res. 2008;18:309-327.
20. Wagner A, Vorauer-Uhl K. Liposome technology for industrial purposes. J Drug Deliv. 2011;2011:591325.
21. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13:238-252.
22. New RC. Preparation of liposomes. In: New RC, editor. Liposomes: A Practical Approach. New York: Oxford University Press; 1990.
23. Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A. 1978;75:4194-4198.
24. Batzri S, Korn ED. Single bilayer liposomes prepared without sonication. Biochim Biophys Acta. 1973;298:1015-1019.
25. Deamer D, Bangham AD. Large volume liposomes by an ether vaporization method. Biochim Biophys Acta. 1976;443:629-634.
26. Lasch J, Weissig V, Brandl M. Preparation of liposomes. In: Torchilin V, Weissig V, editors. Liposomes: A Practical Approach. New York: Oxford University Press; 2003.
27. Brunner J, Skrabal P, Hausser H. Single bilayer vesicles prepared without sonication physicochemical properties. Biochim Biophys Acta. 1976;455:322-331.
28. Kirby C, Gregoriadis G. Dehydration-rehydration vesicles: a simple method for high-yield drug entrapment in liposomes. Nat Biotechnol. 1984;2:979-984.
29. Woodbury DJ, Richardson ES, Grigg AW, Welling RD, Knudson BH. Reducing liposome size with ultrasound: bimodal size distributions. J Liposome Res. 2006;16:57-80.
30. Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure-characterization of size distribution, trapped volume and ability to maintain a membrane-potential. Biochim Biophys Acta. 1985;812:55-65.
31. Berger N, Sachse A, Bender J, Schubert R, Brandl M. Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int J Pharm. 2001;223:55-68.
32. MacDonald RC, MacDonald RI, Menco BP, Takeshita K, Subbarao NK, Hu LR. Small volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta. 1991;1061:297-303.
33. Bachmann D, Brandl M, Gregoriadis G. Preparation of liposomes using a mini-lab 8.30 H high-pressure homogenizer. Int J Pharm. 1993;91: 69-74.
34. Laouini A, Jaafar-Maalej C, Limayem-Blouza I, Sfar S, Charcosset C, Fessi H. Preparation, characterization and applications of liposomes: state of the art. J Colloid Sci Biotechnol. 2012;1:147-168.
35. Stone HA, Stroock AD, Adjari A. Engineering flows in small devices: microfluidics toward a lab-on-a-chip. Annu Rev Fluid Mech. 2004;36: 381-411.
36. Whitesides GM. The origins and the future of microfluidics. Nature. 2006;442:368-373.
37. Yu B, Lee RJ, Lee LJ. Microfluidic methods for production of liposomes. Methods Enzymol. 2009;465:129-141.
38. Hood RR, Vreeland WN, DeVoe DL. Microfluidic remote loading for rapid single-step liposomal drug preparation. Lab Chip. 2014;14: 3359-3367.
39. Tarabella G, Balducci AG, Coppedè N, et al. Liposomes sensing and monitoring by organic electrochemical transistors integrated in microfluidics. Biochim Biophys Acta. 2013;1830:4374-4380.
40. Lasic DD. Magnetic resonance methods in the studies of liposomes. Bull Magn Reson. 1991;13:3-13.
41. Ostrovsky N. Liposome size measurements by photon correlation spectroscopy. Chem Phys Lipids. 1993;64:45-56.
42. Palmer AF, Wingert P, Nickels J. Atomic force microscopy and light scattering of small unilamellar actin-containing liposomes. Biophys J. 2003;85:1233-1247.
43. Grabielle-Madelmont C, Lesieur S, Ollivon M. Characterization of loaded liposomes by size exclusion chromatography. J Biochem Biophys Methods. 2003;56:189-217.
44. Moon MH, Giddings JC, Pharm J. Size distribution of liposomes by flow field-flow fractionation. J Pharm Biomed Anal. 1993;11:911-920.
45. Ruozi B, Belletti D, Tombesi A, et al. AFM, ESEM, TEM, and CLSM in liposomal characterization: a comparative study. Int J Nanomedicine. 2011;6:557-563.
46. Frederik PM, Hubert DH. Cryoelectron microscopy of liposomes. Methods Enzymol. 2005;391:431-448.
47. Jass J, Tjärnhage T, Puu G. Atomic force microscopy imaging of liposomes. Methods Enzymol. 1993;367:199-213.
48. Ruozi B, Tosi G, Forni F, et al. Atomic force microscopy and photon correlation spectroscopy: two techniques for rapid characterization of liposomes. Eur J Pharm Sci. 2005;25:81-89.
49. Ruysschaert T, Marque A, Duteyrat JL, Lesieur S, Winterhalter M, Fournier D. Liposome retention in size exclusion chromatography. BMC Biotechnol. 2005;10:5-11.
50. Korgel BA, Van Zanten JH, Monbouquette HG. Vesicle size distributions measured by flow field-flow fractionation coupled with multiangle light scattering. Biophys J. 1998;74:3264-3272.
51. Mohan A, Narayanan S, Sethuraman S, Krishnan UM. Novel resveratrol and 5-fluorouracil coencapsulated in pegylated nanoliposomes improve chemotherapeutic efficacy of combination against head and neck squamous cell carcinoma. Biomed Res Int. 2014;2014: 424239.
52. Storm G, Roerdink FH, Steerenberg PA, de Jong WH, Crommelin DJ. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res. 1987;47:3366-3372.
53. McIntosh TJ. The effect of cholesterol on the structure of phosphatidylcholine bilayers. Biochim Biophys Acta. 1978;513:43-58.
54. Cullis PR, Hope MJ. The bilayer stabilizing role of sphingomyelin in the presence of cholesterol: a 31P NMR study. Biochim Biophys Acta. 1980;597:533-542.
55. Defrise-Quertain F, Chatelain P, Delmelle M, et al. Model studies for drug entrapment and liposome stability. In: Gregoriadis G, editor. Liposome Technology. Boca Raton (FL): CRC; 1984:1-17.
56. Allen TM, Mehra T, Hansen C, Chin YC. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1992;52:2431-2439.
57. Fahr A, van Hoogevest P, May S, Bergstrand N, Leigh ML. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci. 2005;26: 251-265.
58. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta. 1986;857:123-126.
59. Forssen EA, Malé-Brune R, Adler-Moore JP, et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 1996;56:2066-2075.
60. Johnston MJ, Edwards K, Karlsson G, et al. Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res. 2008;18:145-157.
61. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66:3271-3277.
62. Zhigaltsev IV, Winters G, Srinivasulu M, et al. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release. 2010;144:332-340.
63. Zamboni WC. Concept and clinical evaluation of carrier mediated anticancer agents. Oncologist. 2008;13:248-260.
64. Lasic DD. Novel applications of liposomes. Trends Biotechnol. 1998;16:307-321.
65. Silverman JA, Reynolds L, Deitcher SR. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia. J Clin Pharmacol. 2013;53:1139-1145.
66. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009;69:361-392.
67. Nasti TH, Khan MA, Owais M. Enhanced efficacy of pH sensitive nystatin liposomes against Cryptococcus neoformans in murine model. J Antimicrob Chemother. 2006;57:349-352.
68. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999;51:691-743.
69. Lao J, Madani J, Puértolas T, et al. Liposomal doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv. 2013;2013:456409.
70. Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol. 2012;1:10.
71. Pisano C, Cecere SC, Di Napoli M, et al. Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer. J Drug Deliv. 2013;2013:898146.
72. Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000;18:3093-3100.
73. Katsumata N, Fujiwara Y, Kamura T, et al. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a phase II study of the Japanese Gynecologic Oncology Group. Jpn J Clin Oncol. 2008;38:777-785.
74. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol. 2000;78:369-372.
75. Lotem M, Hubert A, Lyass O, et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol. 2000;136:1475-1480.
76. Alberts DS. Muggia FM, Carmichael J, et al. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol. 2004;31:53-90.
77. Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am. 1994;8:431-450.
78. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
79. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444-1454.
80. O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440-449.
81. Gabizon AA, Lyass O, Berry GJ, Wildgust M. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest. 2004;22:663-669.
82. Mustafa MH. Decreased risk of cardiotoxicity with long-term use of Doxil/Caelyx at high lifetime cumulative doses in patients with AIDS-related Kaposi/Es sarcoma (KS). Poster presented at: ASCO Annual Meeting 2001; May 12-15, 2001; San Francisco, CA.
83. Andreopoulou E, Gaiotti D, Kim E, et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol. 2007;18:716-721.
84. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131-135.
85. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156:1363-1380.
86. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55:3752-3756.
87. Brown S, Khan DR. The treatment of breast cancer using liposome technology. J Drug Deliv. 2012;2012:212965.
88. Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol. 1998;153:1239-1248.
89. O’Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL. Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. 2004;209:171-176.
90. Woodle MC, Matthay KK, Newman MS, et al. Versatility in lipid compositions showing prolonged circulation with sterically stabilized liposomes. Biochim Biophys Acta. 1992;1105:193-200.
91. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of PEGylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42:419-436.
92. Ishida T, Harashima H, Kiwada H. Liposome clearance. Biosci Rep. 2002;22:197-224.
93. Semple SC, Harasym TO, Clow KA, Ansell SM, Klimuk SK, Hope MJ. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther. 2005;312:1020-1026.
94. Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res. 2006;16:175-183.
95. Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IA, Scherphof GL. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer. 1995;61:716-721.
96. Juliano RL, Stamp D. Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin. Biochem Pharmacol. 1978;27: 21-27.
97. Gabizon AA. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res. 2001;7:223-225.
98. Bedu-Addo FK, Tang P, Xu Y, Huang L. Effects of polyethyleneglycol chain length and phospholipid acyl chain composition on the interaction of polyethyleneglycol-phospholipid conjugates with phospholipid: implications in liposomal drug delivery. Pharm Res. 1996;13:710-717.
99. Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release. 2003;90:323-334.
100. Harris JM, editor. Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications. New York: Plenum;1992.
101. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 1995;16:215-233.
102. Moghimi SM, Hedeman H, Muir IS, Illum L, Davis SS. An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. Biochim Biophys Acta. 1993;1157:233-240.
103. Harris JM, Martin NE, Modi M. PEGylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet. 2001;40:539-551.
104. Wu H, Ramanathan RK, Zamboni BA, et al. Population pharmacokinetics of PEGylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. J Clin Pharmacol. 2011;52:180-194.
105. Heyes J, Hall K, Tailor V, Lenz R, MacLachlan I. Synthesis and characterization of novel poly(ethylene glycol)-lipid conjugates suitable for use in drug delivery. J Control Release. 2006;112:280-290.
106. Allen TM. Liposomes. Opportunities in drug delivery. Drugs. 1997;54:8-14.
107. Gabizon AA. PEGylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001;19:424-436.
108. Dawidczyk CM, Kim C, Park JH, et al. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release. 2014;187:133-144.
109. Andresen TL, Jensen SS, Jørgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res. 2005;44:68-97.
110. Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface Sci. 2011;6:66-77.
111. Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs. 1999;10:911-920.
112. Asai T, Oku N. Angiogenic vessel-targeting DDS by liposomalized oligopeptides. Methods Mol Biol. 2010;605:335-347.
113. Gabizon A, Tzemach D, Gorin J, et al. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol. 2010;66:43-52.
114. Garg A, Tisdale AW, Haidari E, Kokkoli E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. Int J Pharm. 2009;366:201-210.
115. Vingerhoeds MH, Haisma HJ, van Muijen M, van de Rijt RB, Crommelin DJ, Storm G. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs. FEBS Lett. 1993;336:485-490.
116. Noble GT, Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014;32:32-45.
117. Fanciullino R, Giacometti S, Aubert C, et al. Development of stealth liposome formulation of 2′-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study. Pharm Res. 2005;22:2051-2057.
118. Senior JH, Trimble KR, Maskievicz R. Interaction of positively charged liposomes with blood: implications for their application in vivo. Biochim Biophys Acta. 1991;1070:173-179.
119. Zhao W, Zhuang S, Qi XR. Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int J Nanomedicine. 2011;6:3087-3098.
120. Harashima H, Matsuo H, Kiwada H. Identification of proteins mediating clearance of liposomes using a liver perfusion system. Adv Drug Delivery Rev. 1998;32:61-79.
121. Miller CR, Bondurant B, McLean SD, McGovern KA, O’Brien DF. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry. 1998;37:12875-12883.
122. Cullis PR, Chonn A, Semple SC. Interactions of liposome and lipid-based carrier systems with blood proteins: relation to clearance behavior in vivo. Adv Drug Delivery Rev. 1998;32:3-17.
123. Campbell PI. Toxicity of some charged lipids used in liposome preparations. Cytobios. 1983;37:21-26.
124. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature. 1974;252:252.
125. Nakanishi T, Kunisawa J, Hayashi A, et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Control Release. 1999;61: 233-240.
126. Afrin F, Rajesh R, Anam K, Gopinath M, Pal S, Ali N. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect Immun. 2002;70:6697-6706.
127. Badiee A, Jaafari MR, Khamesipour A, et al. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63). Exp Parasitol. 2009;121:362-369.
128. González-Rodríguez ML, Rabasco AM. Charged liposomes as carriers to enhance the permeation through the skin. Expert Opin Drug Deliv. 2011;8:857-871.
129. Ogiso T, Yamaguchi T, Iwaki M, Tanino T, Miyake Y. Effect of positively and negatively charged liposomes on skin permeation of drugs. Drug Target. 2001;9:49-59.
130. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient lipid-mediated DNA transfection procedure. Proc Natl Acad Sci U S A. 1987;84:7413-7417.
131. Bombelli C, Caracciolo G, Di Profio P, et al. Inclusion of a photosensitizer in liposomes formed by DMPC/gemini surfactant: correlation between physicochemical and biological features of the complexes. J Med Chem. 2005;48:4882-4891.
132. Strieth S, Eichhorn ME, Sauer B, et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer. 2004;110:117-124.
133. Wu J, Lee A, Lu Y, Lee RJ. Vascular targeting of doxorubicin using cationic liposomes. Int J Pharma. 2007;337:329-335.
134. Campbell RB, Fukumura D, Brown EB, et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 2002;62:6831-6836.
135. Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci. 2009;98:411-429.
136. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx. 2005;2:99-107.
137. Krasnici S, Werner A, Eichhorn ME, et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer. 2003;105:561-567.
138. Stamatatos L, Leventis R, Zuckermann MJ, Silvius JR. Interactions of cationic lipid vesicles with negatively charged phospholipid vesicles and biological membranes. Biochemistry. 1988;27:3917-3925.
139. Litzinger DC, Brown JM, Wala I, et al. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta. 1996;1281:139-149.
140. McLean JW, Fox EA, Baluk P, et al. Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice. Am J Physiol. 1997;273:H387-H404.
141. Dass CR. Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature. Int J Pharm. 2003;267:1-12.
142. Meyer O, Kirpotin D, Hong K, et al. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J Biol Chem. 1998;273:15621-15627.
143. Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol. 2001;167:3324-3328.
144. Skupin-Mrugalska P, Piskorz J, Goslinski T, Mielcarek J, Konopka K, Düzgünes¸ N. Current status of liposomal porphyrinoid photosensitizers. Drug Discov Today. 2013;18:776-784.
145. Molinari A, Bombelli C, Mannino S, et al. m-THPC-mediated photodynamic therapy of malignant gliomas: assessment of a new transfection strategy. Int J Cancer. 2007;121:1149-1155.
146. Bombelli C, Stringaro A, Borocci S, et al. Efficiency of liposomes in the delivery of a photosensitizer controlled by the stereochemistry of a gemini surfactant component. Mol Pharm. 2010;7:130-137.
147. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm. 2009;71:431-444.
148. Perche F, Torchilin VP. Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv. 2013;2013:705265.
149. Gullino PM, Grantham FH, Smith SH, Haggerty AC. Modifications of the acid-base status of the internal milieu of tumors. J Natl Cancer Inst. 1965;34:857-869.
150. Simões S, Moreira JN, Fonseca C, Düzgünes¸ N, de Lima MC. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev. 2004;56:947-965.
151. Caldeira de Araújo Lopes S, Vinícius Melo Novais M, Salviano Teixeira C, et al. Preparation, physicochemical characterization, and cell viability evaluation of long-circulating and pH-sensitive liposomes containing ursolic acid. Biomed Res Int. 2013;2013:467147.
152. Ong W, Yang Y, Cruciano AC, McCarley RL. Redox-triggered contents release from liposomes. J Am Chem Soc. 2008;130:14739-14744.
153. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 1978;202:1290-1293.
154. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev. 2001;53:285-305.
155. Li L, ten Hagen TL, Schipper D, et al. Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia. J Control Release. 2010;143:274-279.
156. Kong G, Anyarambhatla G, Petros WP, et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000;60:6950-6957.
157. Thanou M, Gedroyc W. MRI-guided focused ultrasound as a new method of drug delivery. J Drug Deliv. 2013;2013:616197.
158. Evans E, Needham D. Physical properties of surfactant bilayer membranes: thermal transitions, elasticity, rigidity, cohesion, and colloidal interactions. J Phys Chem. 1987;91:4219-4228.
159. Kono K. Thermosensitive polymer-modified liposomes. Adv Drug Deliv Rev. 2001;53:307-319.
160. Gasselhuber A, Dreher MR, Negussie A, Wood BJ, Rattay F, Haemmerich D. Mathematical spatio-temporal model of drug delivery from low temperature sensitive liposomes during radiofrequency tumour ablation. Int J Hyperthermia. 2010;26:499-513.
161. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother. 2009;10:333-343.
162. Dromi S, Frenkel V, Luk A, et al. Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res. 2007;13:2722-2727.
163. Hauck ML, LaRue SM, Petros WP, et al. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res. 2006;12:4004-4010.
164. Kheirolomoom A, Lai CY, Tam SM, et al. Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia. J Control Release. 2013;172:266-273.
165. Wang LS, Chuang MC, Ho JA. Nanotheranostics-a review of recent publications. Int J Nanomedicine. 2012;7:4679-4695.
166. Sumer B, Gao J. Theranostic nanomedicine for cancer. Nanomedicine (Lond). 2008;3:37-140.
167. Deveza L, Choi J, Yang F. Therapeutic angiogenesis for treating cardiovascular diseases. Theranostics. 2012;2:801-814.
168. Janib SM, Moses AS, MacKay JA. Imaging and drug delivery using theranostic nanoparticles. Adv Drug Deliv Rev. 2010;2:1052-1063.
169. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012;2:3-44.
170. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010;62:1064-1079.
171. Ye Y, Chen X. Integrin targeting for tumor optical imaging. Theranostics. 2011;1:102-126.
172. Al-Jamal WT, Kostarelos K. Liposome-nanoparticle hybrids for multimodal diagnostic and therapeutic applications. Nanomedicine (Lond). 2007;2:85-98.
173. Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res. 2011;44:1094-1104.
174. Nie Y, Ji L, Ding H, et al. Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization. Theranostics. 2012;2:1092-1103.
175. Leung SJ, Romanowski M. Light-activated content release from liposomes. Theranostics. 2012;2:1020-1036.
176. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145-160.
177. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes-improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A. 1991;88:11460-11464.
178. Al-Jamal WT, Al-Jamal KT, Tian B, et al. Lipid-quantum dot bilayer vesicles enhance tumor cell uptake and retention in vitro and in vivo. ACS Nano. 2008;2:408-418.
179. Soenen SJ, Vande Velde G, Ketkar-Atre A, Himmelreich U, De Cuyper M. Magnetoliposomes as magnetic resonance imaging contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3:197−211.
180. Kamaly N, Miller AD. Paramagnetic liposome nanoparticles for cellular and tumour imaging. Int J Mol Sci. 2010;11:1759−1776.
181. Li S, Goins B, Zhang L, Bao A. Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging. Bioconjug Chem. 2012;23:1322−1332.
182. Muthu MS, Kulkarni SA, Raju A, Feng SS. Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials. 2012;33:3494-3501.
183. Wen CJ, Zhang LW, Al-Suwayeh SA, Yen TC, Fang JY. Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int J Nanomedicine. 2012;7:1599-1611.
184. Wen CJ, Sung CT, Aljuffali IA, Huang YJ, Fang JY. Nanocomposite liposomes containing quantum dots and anticancer drugs for bioimaging and therapeutic delivery: a comparison of cationic, PEGylated and deformable liposomes. Nanotechnology. 2013;24:325101.
185. Smith B, Lyakhov I, Loomis K, et al. Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). J Control Release. 2011;153:187-194.
186. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670-1680.
187. Svenson S. Theranostics: are we there yet? Mol Pharm. 2013;10:848-856.
188. Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117-134.
189. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49-60.
190. Mross K, Niemann B, Massing U, et al. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol. 2004;54:514-524.
191. Stegmann T, Morselt HW, Booy FP, van Breemen JF, Scherphof G, Wilschut J. Functional reconstitution of influenza virus envelopes. EMBO J. 1987;6:2651-2659.
192. Glück R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ Jr. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest. 1992;90:2491-2495.
193. Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci. 2008;70:269-277.
194. Löhr JM, Haas SL, Bechstein WO, et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann Oncol. 2012;23:1214-1222.
195. White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer. 2006;95:822-828.
196. Booser DJ, Esteva FJ, Rivera E, et al. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol. 2002;50:6-8.
197. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat Biotechnol. 2006;24:1211-1218.
198. Bawa R. Nanoparticle-based therapeutics in humans: a survey. NLB. 2008;5:135-155.
199. Faraji AH, Wipf P. Nanoparticles in cellular drug delivery. Bioorg Med Chem. 2009;17:2950-2962.
200. Sigma-Tau Pharmaceuticals, Inc.-Producs (Website). Available from: http://www.sigmatau.com/products/abelcet_rx.asp. Accessed Sep 04, 2013.
201. Ambisome (amphotericin B) liposome for injection (Website). Available from: http://www.ambisome.com/. Accessed Sep 03, 2013.
202. Tollemar J, Ringden O. Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Drug Saf. 1995;13:207-218.
203. Samaritan Pharmaceuticals (Website). Available from: http://www.samaritanpharma.com/amphocil/. Accessed Sep 03, 2013.
204. Griese N, Blaschke G, Boos J, Hempel G. Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis. J Chromatogr A. 2002;979:379-388.
205. DaunoXome (Website). Available from: http://daunoxome.com/. Accessed Sep 05, 2013.
206. Bao A, Goins B, Klipper R, Negrete G, Phillips WT. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther. 2004;308:419-425.
207. Doxil (Website). Available from: http://www.doxil.com/. Accessed Sep 05, 2013.
208. Visudyne (Website). Available from: http://www.visudyne.com/. Accessed Sep 05, 2013.
209. Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep. 2001;3:156-162.
210. TLC-Product (Website). Cited: 2011 Mar 31. Available from: http://www.tlcbio.com/en/product.html
211. Crucell (Website). Available from: http://www.crucell.com/Products. Accessed Oct 2, 2013.
212. Patil SD, Burgess DJ. Liposomes, design and manufacturing. In: Burgess DJ, editor. Injectable Dispersed Systems: Formulation, Processing and Performance (Drugs and The Pharmaceutical Sciences Series). New York: Marcel Dekker; 2005:249-303.
213. Pacira Pharmaceuticals, INC-Produtcs (Website). Cited: 2013 Sep 3. Aivable from: http://www.pacira.com/products/depodur.php
214. NCT00002742. Antifungal therapy for fever and neutropenia in patients receiving treatment for hematologic cancer (Clinical Trial). ClinicalTrials.gov.
215. Moribe K, Maruyama K. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease. Curr Pharm Des. 2002;8:441-454.
216. NCT00364676. Study of Vinorelbine liposomes injection for advanced solid tumors, non Hodgkin’s lymphoma or Hodgkin’s disease (Clinical Trial). ClinicalTrials.gov.
217. Talon Therapeutics, Inc. (Website). Talon product portfolio. Available from: http://www.talontx.com/pipeline.php. Accessed Sep 03, 2013.
218. NCT01652859. An bioequivalence study to compare two 2 mg/mL liposomal Amphotericin B injections in healthy subjects (Clinical Trial). ClinicalTrials.gov.
219. NCT00043199. A safety and effectiveness study of aroplatin in patients with advanced colorectal cancer resistant to standard therapies (Clinical Trial). ClinicalTrials.gov.
220. Lu C, Perez-Soler R, Piperdi B, et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol. 2005;23:3495-3501.
221. Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol. 2006;58:759-764.
222. NCT01041235. Safety study of a liposomal docetaxel formulation in patients with solid tumors who have failed previous therapies (Clinical Trial). ClinicalTrials.gov.
223. Azaya Therapeutics Products (Website). Available from: http://www.azayatherapeutics.com/about-us/products. Accessed Sep 06, 2013.
224. NCT00005969. Liposomal tretinoin in treating patients with recurrent or refractory Hodgkin’s disease (Clinical Trial). ClinicalTrials.gov.
225. Manconi M, Sinico C, Valenti D, Loy G, Fadda AM. Niosomes as carriers for tretinoin-Preparation and properties. Int J Pharm. 2002;34:237-248.
226. Aleku M, Schulz P, Keil O, et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 2008;68:9788.
227. Li L, Shen Y. Overcoming obstacles to develop effective and safe siRNA therapeutics. Expert Opin Biol Ther. 2009;9:609-619.
228. Silence Therapeutics (Website). Available from: http://silence-therapeutics.com/pipeline/pre clinical-development/. Accessed Sep 06, 2013.
229. NCT00245297. Study of the efficacy of human recombinant factor VIII (Kogenate FS) reconstituted in pegylated liposomes (Clinical Trial). ClinicalTrials.gov.
230. Powell J, Nugent D, Harrison J, et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost. 2008;6:277-283.
231. NCT01159028. Clinical trial of L-Grb-2 antisense oligonucleotide in CML, AML, ALL and MDS (Clinical Trial). ClinicalTrials.gov.
232. Bio-Path Holdings, Inc (Website). Available from: http://www.biopathholdings.com/pdf/factsheetv1.pdf. Accessed Sep 06, 2013.
233. NCT00765973. Topotecan liposomes injection for small cell lung cancer (SCLC), ovarian cancer and other advanced solid tumors (Clinical Trial). ClinicalTrials.gov.
234. NCT00361842. Multicenter study Of CPX-1 (Irinotecan HCl: Floxuridine) liposome injection in patients with advanced colorectal cancer (Clinical Trial). ClinicalTrials.gov.
235. Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007;7:216-223.
236. NCT00875693. A novel sequential treatment of salvage and reduced intensity conditioning (RIC) chemotherapy for allogeneic stem-cell transplantation (SCT) for primary refractory and relapsed acute myelogenous leukemia (AML) (Clinical Trial). ClinicalTrials.gov.
237. NCT00968604. C-VISA BikDD: liposome in advanced pancreatic cancer (Clinical Trial). ClinicalTrials.gov.
238. Xie X, Xia W, Li Z, et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell. 2007;12:52.
239. Matsumura Y. Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles. J Drug Target. 2007;15:507-517.
240. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest. 1998;101:1401-1413.
241. NCT00364143. Safety study of IHL-305 (Irinotecan Liposome Injection) to treat advanced solid tumors (ClinicalTrial). ClinicalTrials.gov.
242. NCT00059605. Phase I study of IV DOTAP: cholesterol-Fus1 in non-small-cell lung cancer. (ClinicalTrial). ClinicalTrials.gov.
243. NCT00860522. JVRS-100 for the treatment of patients with relapsed or refractory leukemia (ClinicalTrial). ClinicalTrials.gov.
244. Chang S, Warner J, Liang L, Fairman J. A novel vaccine adjuvant for recombinant flu antigens. Biologicals. 2009;37:141-147.
245. NCT00271063. Study of Liposomal Annamycin in Patients With Refractory or Relapsed Acute Lymphocytic Leukemia (ClinicalTrial). ClinicalTrials.gov.
246. Booser DJ, Esteva FJ, Rivera E, et al. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer. Cancer Chemother Pharmacol. 2002;50:6-8.
247. Neopharm, Inc. Products-Neopharm (Website). Available from: www.neopharm.com/products/. Accessed Sep 06, 2013.
248. NCT00024492. Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer (Clinical Trial). ClinicalTrials.gov.
249. NCT01190982. Efficacy and safety study of LEP-ETU to treat metastatic breast cancer (Clinical Trial). ClinicalTrials.gov.
250. Zhang JA, Anyarambhatla G, Ma L, et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm. 2005;59:177-187.
251. NCT00024648. Study to determine maximum tolerated dose of LErafAON combined with radiotherapy in patients with advanced malignancies (Clinical Trial). ClinicalTrials.gov.
252. NCT00035867. Study of TLK199 HCl liposomes for injection in myelodysplastic syndrome (Clinical Trial). ClinicalTrials.gov.
253. Rudin CM, Marshall JL, Huang CH, et al. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors. Clin Cancer Res. 2004;10:72447-77251.
254. NCT00104754. Liposomal SN-38 in treating patients with small cell lung cancer (Clinical Trial). ClinicalTrials.gov.
255. Zhang JA, Xuan T, Parmar M, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm. 2004;270:93-107.
256. NCT01159028. Clinical trial of L-Grb-2 antisense oligonucleotide in CML, AML, ALL and MDS (Clinical Trial). ClinicalTrials.gov.
257. Tari AM, Gutiérrez-Puente Y, Monaco G, et al. Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts. Int J Oncol. 2007;31:1243-1250.
258. Fantini M, Gianni L, Santelmo C, et al. Lipoplatin treatment in lung and breast cancer. Chemother Res Pract. 2011;2011:125192.
259. Stathopoulos GP, Boulikas T, Vougiouka M, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep. 2005;13:589-595.
260. Farhat FS, Temraz S, Kattan J, et al. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer. Clin Breast Cancer. 2011;11:384-389.
261. NCT00739466. Biorest Liposomal Alendronate With Stenting sTudy (BLAST) (Clinical Trial). ClinicalTrials.gov.
262. NCT00747474. Phase i study of intravenous LipotecanR (TLC388 HCl for Injection) in patients with advanced solid tumors (Clinical Trial). ClinicalTrials.gov.
263. Huang ZR, Hua SC, Yang YL, Fang JY. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin. 2008;29:1094-1102.
264. NCT01052142. Safety study of a liposomal vaccine to treat malignant melanoma (Clinical Trial). ClinicalTrials.gov.
265. Herringson TP, Altin JG. Convenient targeting of stealth siRNA-lipoplexes to cells with chelator lipid-anchored molecules. J Control Release. 2009;139:229-238.
266. NCT00053716. Prostaglandin E1 (Liprostin) treatment with lower limb angioplasty for peripheral arterial occlusive disease (Clinical Trial). ClinicalTrials.gov.
267. NCT00631631. L-MTP-PE for high-risk osteosarcoma (Clinical Trial). ClinicalTrials.gov.
268. Jain V, Vyas SP, Kohli DV. Well-defined and potent liposomal hepatitis B vaccines adjuvanted with lipophilic MDP derivatives. Nanomedicine. 2009;5:334-344.
269. NCT00144963. Liposomal Vincristine plus Dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (Clinical Trial). ClinicalTrials.gov.
270. NCT00964080. Study of MBP-426 in Patients with second line gastric, gastroesophageal, or esophageal adenocarcinoma (Clinical Trial). ClinicalTrials.gov.
271. Mebiopharm-Product and Technologies (Website). Available from: http://www.mebiopharm.com/english/pro.html. Accessed Sep 06, 2013.
272. Hamaguchi T, Matsumura Y, Nakanishi Y, Muro K, Yamada Y, Shimada Y, et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci. 2004;95:608-613.
273. NCT00294996. Trial of Myocet in Metastatic Breast Cancer (Clinical Trial). ClinicalTrials.gov.
274. NCT01039103. Nanocort in acute exacerbation of relapsing-remitting Multiple Sclerosis (MS). (Clinical Trial). ClinicalTrials.gov.
275. Chow T-H, Lin Y-Y, Hwang J-J, Wang H-E, Tseng Y-L, Pang VF, et al. Therapeutic efficacy evaluation of 111 in-labeled PEGylated liposomal vinorelbine in murine colon carcinoma with multimodalities of molecular imaging. J Nucl Med. 2009;50:2073-2081.
276. NCT00038207. Liposomal Vincristine for pediatric and adolescent patients with relapsed malignancies (Clinical Trial). ClinicalTrials.gov.
277. Gelmon KA, Tolcher A, Diab AR, et al. Phase I study of liposomal vincristine. J Clin Oncol. 1999;17:697-705.
278. NCT00046787. Efficacy and safety study of OSI-211 (Liposomal Lurtotecan) to treat recurrent small cell lung cancer (Clinical Trial). ClinicalTrials.gov.
279. NCT00940758. Phase I and pharmacokinetic study of biweekly PEP02 in mCRC refractory to 1st-line oxaliplatin base therapy (Clinical Trial). ClinicalTrials.gov.
280. NCT01191775. A Study of PNT2258 in patients with advanced solid tumors (Clinical Trial). ClinicalTrials.gov.
281. NCT01054547. Topical formulations of liposomal local anesthetics (Clinical Trial). ClinicalTrials.gov.
282. Bexion Pharmaceuticals (Website). Available from: http://www.bexionpharma.com/. Accessed Sep 06, 2013.
283. Qi X, Chu Z, Mahller YY, Stringer KF, Witte DP, Cripe TP. Cancer-Selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C Protein. Clin Cancer Res. 2009;15:5840-5851.
284. Wojton J, Chu Z, Mathsyaraja H, et al. Systemic Delivery of SapC-DOPS Has Antiangiogenic and Antitumor Effects Against Glioblastoma. Mol Ther. 2013;21:1517-1525.
285. NCT00177281. Safety study of S-CKD602 in patients with advanced malignancies. (Clinical Trial). ClinicalTrials.gov.
286. NCT00157209. Phase IIb randomized controlled study of blp25 liposome vaccine for immunotherapy of non-small cell lung cancer (Clinical Trial). ClinicalTrials.gov.
287. NCT00617981. Phase 3 Study of ThermoDox with Radiofrequency Ablation (RFA) in treatment of Hepatocellular Carcinoma (HCC) (Clinical Trial). ClinicalTrials.gov.
288. Celsion Corporation (Website). Available from: http://celsion.com/docs/pipeline_overview. Accessed Sep 06, 2013.
289. NCT00927459. Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of liposomal siRNA in subjects with high cholesterol (Clinical Trial). ClinicalTrials.gov.
290. Rossi JJ. RNAi therapeutics: SNALPing siRNAs in vivo. Gene Ther. 2006;13:583-584.
291. Tekmira Pharmaceuticals Corporation-Products (Website). Available from: http://www.tekmirapharm.com/Programs/Products.asp. Accessed Sep 06, 2013.
292. NCT00089180. T4N5 liposomal lotion in preventing the recurrence of nonmelanoma skin cancer in patients who have undergone a kidney transplant (Clinical Trial). ClinicalTrials.gov.
293. Cafardi JA, Elmets CA. T4 endonuclease V: review and application to dermatology. Expert Opin Biol Ther. 2008;8:829-838.
294. NCT01050777. Efficacy of topical liposomal form of drugs in cutaneous leishmaniasis (Clinical Trial). ClinicalTrials.gov.
295. NCT00764361. Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers (Clinical Trial). ClinicalTrials.gov.
296. Nanotherapeutics-Products (Website). Available from: http://www.nanotherapeutics.com/?q=products_nanodox. Accessed Sep 06, 2013.
297. NCT00089180. T4N5 liposomal lotion in preventing the recurrence of nonmelanoma skin cancer in patients who have undergone a kidney transplant (Clinical Trial). ClinicalTrials.gov.
298. Yarosh D, Klein J, O’Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xenoderma pigmentosum study group. Lancet. 2001;357:926-929.
299. NCT00709254. Study of single and multiple doses of inhaled AeroLEF (Liposome-Encapsulated Fentanyl) in healthy subjects (Clinical Trial). ClinicalTrials.gov.
300. NCT00775138. A Study to Determine the Safety and Tolerability of Arikace™ Versus Placebo in Patients Who Have Bronchiectasis.
301. NCT00492141. Aerosol L9-NC and temozolomide in ewing’s sarcoma (Clinical Trial). ClinicalTrials.gov.
302. NCT00915187. Safety and immunogenicity study of intramuscular CCS/C-adjuvanted influenza vaccine in elderly (Clinical Trial). ClinicalTrials.gov.
303. NCT00922363. Trial on the safety of a new liposomal adjuvant system, CAF01, when given with the tuberculosis subunit vaccine Ag85B-ESAT-6 as two injections with two months interval to healthy adult volunteers (Clinical Trial). ClinicalTrials.gov.
304. NCT00460525. Phase II AMA-1 malaria vaccine FMP2.1/AS02A trial in mali (Clinical Trial). ClinicalTrials.gov.
305. NCT00004806. Phase I Study of liposome-mediated gene transfer in patients with cystic fibrosis (Clinical Trial). ClinicalTrials.gov.
306. NCT00533637. Taste and local tolerance study of NLA nasal spray in patients with allergic rhinitis (Clinical Trial). ClinicalTrials.gov.
307. Orexo AB-OX-NLA (Website). Available from: http://www.orexo.com/en/Portfolio/OX-NLA/. Accessed Sep 05, 2013.
308. NCT00004471. Phase I pilot study of gene therapy for cystic fibrosis using cationic liposome mediated gene transfer (Clinical Trial). ClinicalTrials.gov.
309. NCT01095848. A phase I safety study of a cancer vaccine to treat HLA-a2 positive advanced stage ovarian, breast and prostate cancer (Clinical Trial). ClinicalTrials.gov.
310. NCT00004104. Vaccine therapy plus interleukin-2 with or without interferon alfa-2b in treating patients with stage III melanoma (Clinical Trial). ClinicalTrials.gov.
311. NCT01073371. Anesthetic efficacy of liposomal prilocaine in maxillary infiltration anesthesia (Clinical Trial). ClinicalTrials.gov.
312. Saia Cereda CM, Tofoli GR, de Brito Junior RB, et al. Stability and local toxicity evaluation of a liposomal prilocaine formulation. J Liposome Res. 2008;18:329-339.
313. NCT01334892. L-CsA in the prevention of bronchiolitis obliterans syndrome (BOS) in lung transplant (LT) patients (Clinical Trial). ClinicalTrials.gov.
314. Behr J, Zimmermann G, Baumgartner R, et al. Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. J Aerosol Med Pulm Drug Deliv. 2009;22:121-130.
315. NCT00035867. Study of TLK199 HCl liposomes for injection in myelodysplastic syndrome (Clinical Trial). ClinicalTrials.gov.